EGFR Inhibitor 2 is primarily used in cancer research and treatment, specifically targeting cancers driven by mutations or overactivity in the epidermal growth factor receptor (EGFR). It is applied in preclinical studies to understand the mechanisms of EGFR signaling pathways and their role in tumor growth and survival. This compound is also utilized in the development of targeted therapies for non-small cell lung cancer (NSCLC), breast cancer, and other malignancies where EGFR dysregulation is a key factor. Additionally, it serves as a tool in drug discovery programs to evaluate the efficacy of new EGFR inhibitors and to study resistance mechanisms to existing therapies.